Below is a summary of the key data being presented at the 2013 American Urological Association annual meeting.
POSTER #985: Value of Cell Cycle Progression (CCP) Score to Predict Biochemical Recurrence (BCR) and Definitive Post-Surgical Pathology
Poster Presentation, Monday, May 6, 2013
Results from this prospectively-designed clinical study show that in patients who underwent radical prostatectomy, PROLARIS (CCP) score correlated significantly with organ confined, local invasive and systemic tumor growth, and these correlations remained after adjusting for Gleason score, PSA level and clinical stage. The PROLARIS score significantly represents real clinically and biologically relevant tumor features qualifying it as a promising biomarker for active surveillance in the post-surgical decision making processes as well as pre-surgical decision making processes as demonstrated in earlier clinical studies.
Key findings from this study demonstrate that the PROLARIS test was:
POSTER #2242: Prognostic Utility of Cell Cycle Progression Score in Men with Prostate Cancer After Primary External Beam Radiation Therapy
- A highly significant predictor of biochemical recurrence;
- Identified as a significant factor in predicting pathologic stage T3 cancer; and
- The best predictor for biochemical recurrence in low risk patients, whereas Gleason score was not significant.
Poster Presentation, Wednesday, May 8, 2013
Results from this prospectively-designed clinical study show that in patients who underwent external beam radiation therapy, the PROLARIS (CCP) score was significantly associated with survival outcome after radiation therapy and provided prognostic information beyond what was available from clinical parameters including Gleason score, PSA level and clinical stage. The PROLARIS score could be used to select high-risk men undergoing radiation treatment who may need combination therapy for their clinically localized prostate cancer.
Key findings from the study include:
About Prostate Cancer
- 57 percent of study subjects from the Durham VA Medical Center were African Americans;
- The PROLARIS score was a significant prognostic variable (the hazard ratio for biochemical recurrence was 2.55);
- The PROLARIS test provides prognostic information that is not provided by standard clinical parameters; and
- The PROLARIS score was significantly associated with prostate cancer specific mortality.
According to the Centers for Disease Control and Prevention (CDC), prostate cancer is one of the most common cancers among men and is a the leading causes of cancer death. Approximately 240,000 cases of prostate cancer are diagnosed and more than 28,000 men die from the cancer annually in the United States.